#USA #San Diego #Novartis #MS Research #Kesimpta

Novartis to Present Innovative Data on Kesimpta at AAN 2025

In an exciting development for the neuroscience community, Novartis is set to showcase new findings at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego, scheduled for April 5-9, 2025. This year's presentation will include groundbreaking data focusing on Kesimpta® (ofatumumab), particularly its long-term safety and effectiveness for individuals diagnosed with relapsing multiple sclerosis (RMS).

Key Highlights of the Presentation

One of the most significant components of Novartis's presentation will be the results derived from the ALITHIOS trial, an open-label extension study, which investigates the long-term consequences of ongoing Kesimpta treatment versus switching from teriflunomide. Over the span of seven years, the data will provide valuable insights into the disability outcomes that RMS patients can expect when continuing treatment with Kesimpta.

Dr. Norman Putzki, the head of Neuroscience Gene Therapy Development at Novartis, expressed enthusiasm about sharing these findings, stating: “We look forward to highlighting various clinical and real-world studies that demonstrate the effectiveness of Kesimpta for those living with RMS. Our commitment to advancing neuroscience research continues to grow as we aim to tackle pressing challenges faced by individuals with neurological conditions.”

Presentation Details

During the meeting, the following presentations will take place:

• - Continuous Ofatumumab Treatment (P7.016): This will discuss how continuous Kesimpta treatment shows consistent safety profiles and delays disability progression in RMS patients, happening on April 7th at 5 - 6 PM PT.
• - Long-Term Safety Analysis (P8.017): Findings will reveal that continuous treatment over six years does not increase the risk of serious infections, scheduled for April 8th at 8 - 9 AM PT.
• - Efficacy in Early Treatment (P11.003): Insights into Kesimpta's effectiveness and safety for individuals early in their disease course will be presented on April 9th at 8 - 9 AM PT.
• - Real-World Data Analysis (P7.013): This study showcases real-world efficacy of Ofatumumab as a first-line treatment in early RMS cases, occurring on April 7th at 5 - 6 PM PT.

Moreover, Novartis will provide updates on other pipeline assets, including remibrutinib, aimed at RMS, and iptacopan, targeting generalized myasthenia gravis.

Advancements in Neuroscience

For over 80 years, Novartis has played a pioneering role in treating neurological disorders, launching several transformative therapies that have positively impacted millions globally. The findings expected to be revealed at AAN highlight the company’s ongoing dedication to innovation in the field of neuroscience, providing hope for MS patients and those suffering from related neurological conditions.

Experts believe that through such rigorous studies and transparent data presentations, Novartis is contributing significantly to understanding and managing RMS more effectively. The company is also focused on maintaining a high standard of care and safety, ultimately aiming to improve the quality of life for patients.

Conclusion

As Novartis gears up for its noteworthy presentations at AAN 2025, the anticipation builds around how the findings on Kesimpta and other developments will influence both research and treatment strategies for RMS. The commitment to transparency and advancing medical science reflects Novartis's mission of transforming medicine to empower patients and healthcare professionals alike.

For further information and detailed updates, please visit the official Novartis website.